Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 2
2010 4
2011 4
2012 3
2013 3
2014 1
2016 1
2018 2
2019 4
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed for Bookshelf ID: 4863662

23 results

Results by year

Filters applied: . Clear all
Page 1
A Case of Severe, Nilotinib-Induced Liver Injury.
Belopolsky Y, Grinblatt DL, Dunnenberger HM, Sabatini LM, Joseph NE, Fimmel CJ. Belopolsky Y, et al. ACG Case Rep J. 2019 Feb 25;6(2):e00003. doi: 10.14309/crj.0000000000000003. eCollection 2019 Feb. ACG Case Rep J. 2019. PMID: 31616712 Free PMC article.
Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study.
Kuo CY, Wang PN, Hwang WL, Tzeng CH, Bai LY, Tang JL, Chang MC, Lin SF, Chen TY, Chen YC, Tan TD, Hsieh CY, Lin C, Lai C, Miljkovic D, Chang CS. Kuo CY, et al. Ther Adv Hematol. 2018 Mar;9(3):65-78. doi: 10.1177/2040620718756603. Epub 2018 Mar 4. Ther Adv Hematol. 2018. PMID: 29531660 Free PMC article.
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D, Tan P, D'Rozario J, Taper J, Powell A, Irving I, Wright M, Branford S, Yeung DT, Anderson L, Gervasio O, Levetan C, Roberts W, Solterbeck A, Traficante R, Hughes T. Hiwase D, et al. Leuk Res. 2018 Apr;67:109-115. doi: 10.1016/j.leukres.2018.02.013. Epub 2018 Feb 21. Leuk Res. 2018. PMID: 29494928 Free article. Clinical Trial.
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Hochhaus A, et al. Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3. Leukemia. 2016. PMID: 26837842 Free PMC article. Clinical Trial.
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G. Hughes TP, et al. Haematologica. 2014 Jul;99(7):1204-11. doi: 10.3324/haematol.2013.091272. Epub 2014 Feb 14. Haematologica. 2014. PMID: 24532039 Free PMC article. Clinical Trial.
23 results